E. Ohman J or Asset Management AB Cuts Position in DexCom, Inc. $DXCM

by · The Markets Daily

E. Ohman J or Asset Management AB trimmed its stake in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 17.6% in the 1st quarter, HoldingsChannel reports. The fund owned 95,192 shares of the medical device company’s stock after selling 20,300 shares during the quarter. E. Ohman J or Asset Management AB’s holdings in DexCom were worth $5,978,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Reflection Asset Management bought a new stake in DexCom during the fourth quarter valued at about $25,000. CVA Family Office LLC raised its holdings in DexCom by 48.5% in the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after purchasing an additional 147 shares in the last quarter. MCF Advisors LLC bought a new position in DexCom in the fourth quarter worth about $32,000. ORG Partners LLC raised its holdings in DexCom by 124.3% in the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock worth $34,000 after purchasing an additional 281 shares in the last quarter. Finally, DV Equities LLC purchased a new stake in shares of DexCom during the fourth quarter valued at about $36,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently weighed in on DXCM shares. Benchmark initiated coverage on shares of DexCom in a report on Monday, May 11th. They issued a “buy” rating and a $77.00 price target on the stock. TD Cowen reiterated a “buy” rating and set a $95.00 price objective (up from $75.00) on shares of DexCom in a research note on Wednesday, June 10th. UBS Group set a $95.00 target price on shares of DexCom in a research report on Wednesday, June 10th. Canaccord Genuity Group set a $82.00 target price on shares of DexCom and gave the company a “buy” rating in a research note on Monday, May 18th. Finally, Citigroup reaffirmed a “buy” rating and issued a $84.00 price target (up from $79.00) on shares of DexCom in a report on Thursday, May 28th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $84.83.

View Our Latest Stock Report on DexCom

DexCom Price Performance

Shares of NASDAQ DXCM opened at $72.47 on Friday. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $89.98. The company has a market cap of $27.96 billion, a PE ratio of 30.97, a P/E/G ratio of 1.13 and a beta of 1.45. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. The business has a 50-day simple moving average of $67.07 and a two-hundred day simple moving average of $67.92.

DexCom (NASDAQ:DXCM – Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.09. The firm had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The company’s revenue for the quarter was up 15.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.32 earnings per share. As a group, equities analysts expect that DexCom, Inc. will post 2.58 EPS for the current fiscal year.

Insider Activity at DexCom

In other DexCom news, insider Kevin R. Sayer sold 26,759 shares of the business’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $72.00, for a total transaction of $1,926,648.00. Following the sale, the insider owned 382,482 shares of the company’s stock, valued at approximately $27,538,704. The trade was a 6.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $74.13, for a total transaction of $296,520.00. Following the transaction, the director owned 52,852 shares in the company, valued at $3,917,918.76. The trade was a 7.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 46,694 shares of company stock worth $3,343,977 in the last 90 days. 0.28% of the stock is owned by insiders.

About DexCom

(Free Report)

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.

Further Reading

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM – Free Report).